Kymera Therapeutics (KYMR) PT Raised to $152 at Stifel on Ph2b BROADEN2 Data
Tweet Send to a Friend
Stifel analyst Alex Thompson raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $152.00 (from $132.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




